Status:
TERMINATED
TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma
Lead Sponsor:
Novartis
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The primary objective of this study is to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT), and safety profile of CHIR-258 when administered to subjects with refractory or rela...
Eligibility Criteria
Inclusion
- Confirmed diagnosis of multiple myeloma
- Evidence of relapsed or refractory disease
Exclusion
- Intracranial disease or epidural disease
- Clinically significant cardiac disease
- Diabetes mellitus
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT00243763
Last Update
November 23 2009
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic - Arizona
Scottsdale, Arizona, United States, 85259
2
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States, 33612
3
Emory University
Atlanta, Georgia, United States, 30322
4
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115